Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 3, 1997, Pages 157-163

  Reichardt, Volker L ^a   Okada, Craig Y ^a   Stockerl Goldstein, Keith E ^a   Bogen, Bjarne ^a,b   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

High dose therapy; Idiotypic vaccination; Multiple myeloma

Indexed keywords

ALKYLATING AGENT; IMMUNOGLOBULIN IDIOTYPE; IMMUNOLOGICAL ADJUVANT; MELPHALAN; MONOCLONAL ANTIBODY;

AUTOTRANSPLANTATION; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN IDIOTYPES; MELPHALAN; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS; VACCINATION;

EID: 0031201101     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Durie BG: Staging and kinetics of multiple myeloma. Semin Oncol 13:300, 1986.
2. Malpas JS, Bergsagel DE, Kyle RA: Myeloma: Biology and Management. New York: Oxford University Press, 1995.
3. Osgood E: The survival time of patients with plasmocytic myeloma. Cancer Chemotherapy Reports 9:1, 1960.
4. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353, 1984.
5. Kyle RA: Long-term survival in multiple myeloma. N Engl J Med 308:314, 1983.
6. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R: High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298, 1986.
7. Jagannath S, Barlogie B: Autologous bone marrow transplantation for multiple myeloma. Hematol Oncol Clin North Am 6:437, 1992.
8. Anderson KC: Who benefits from high-dose therapy for multiple myeloma? J Clin Oncol 13:1291, 1995.
9. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335:91, 1996.
10. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: proof of principle. Blood 87:1196, 1996.
11. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ: Graft-versus-myeloma effect in two cases. Lancet 347:800, 1996.
12. Gahrton G, Tura S, Ljungman P, Blad J, Brandt L, Cavo M, Facon T, Gratwohl A, Hagenbeek A, Jacobs P, De Laurenzi A, Van Lint M, Michallet M, Nikoskelainen J, Reiffers J, Samson D, Verdonck L, De Witte T, Volin L: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13:1312, 1995.
13. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, Chauncey T, Shulman H, Appelbaum FR: Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88:2787, 1996.
14. Björkstrand B, Ljungman P, Svensson H, Hermanns J, Alegre A, Apperley J, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, De Lanrenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European group for blood and marrow transplantation. Blood 88:4711, 1996.
15. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390, 1995.
16. Anderson KC, Andersen J, Soiffer R, Freedman AS, Rabinowe SN, Robertson MJ, Spector N, Blake K, Murray C, Freeman A, Coral F, Marcus KC, Mauch P, Nadler LM, Ritz J: Monoclonal, antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 82:2568, 1993.
17. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B: Autotransplants in multiple myeloma: What have we learned? Blood 88:838, 1996.
18. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789, 1997.
19. Tonegawa S: Somatic generation of antibody diversity. Nature 302:575, 1983.
20. Slater RJ, Ward SM, Kunkel HG: Immunologic relationships among the myeloma proteins. J Exp Med 101:85, 1955.
21. Sirisinha S, Eisen HN: Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci U S A 68:3130, 1971.
22. Rodkey LS: Studies of idiotypic antibodies. Production and characterization of autoantiidiotypic antisera. J Exp Med 139:712, 1974.
23. Jerne NK: Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373, 1974.
24. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN: Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 69:1540, 1972.
25. Croese JW, Vissinga CS, Boersma WJ, Radl J: Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype. Neoplasma 38:457, 1991.
26. Croese JW, Van den Enden-Vieveen MH, Radl J: Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease. Neoplasma 38:467, 1991.
27. Jorgensen T, Gaudernack G, Hannestad K: Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand J Immunol 11:29, 1980.
28. Bridges SH: Participation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol 121:479, 1978.
29. Kaminski MS, Kitamura K, Maloney DG, Levy R: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol 138:1289, 1987.
30. Hannestad K, Kao MS, Eisen HN: Cell-bound myeloma proteins on the surface of myeloma cells: potential targets for the immune system. Proc Natl Acad Sci U S A 69:2295, 1972.
31. Billadeau D, Abmann G, Greipp P, Van Ness B: The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178:1023, 1993.
32. Corradini P, Boccadoro M, Voena C, Pileri A: Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 178:1091, 1993.
33. Bakkus MH, Van Riet I, Van Camp B, Thielemans K: Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 87:68, 1994.
34. Schrater AF, Goidl EA, Thorbecke GJ, Siskind GW: Production of auto-anti-idiotypic antibody during the normal immune response to TNP-ficoll. III. Absence in nu/nu mice: evidence for T-cell dependence of the anti-idiotypic-antibody response. J Exp Med 150:808, 1979.
35. Janeway CA, Jr., Sakato N, Eisen HN: Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci U S A 72:2357, 1975.
36. Jorgensen T, Hannestad K: Specificity of T and B lymphocytes for myeloma protein 315. Eur J Immunol 7:426, 1977.
37. Jorgensen T, Hannestad K: Helper T cell recognition of the variable domains of a mouse myeloma protein (315). Effect of the major histocompatibility complex and domain conformation. J Exp Med 155:1587, 1982.
38. Bogen B, Jorgensen T, Hannestad K: T helper cell recognition of idiotopes on lambda 2 light chains of M315 and T952: evidence for dependence on somatic mutations in the third hypervariable region. Eur J Immunol 15:278, 1985.
39. Bogen B, Malissen B, Haas W: Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 16:1373, 1986.
40. Bogen B, Lambris JD: Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. Embo J 8:1947, 1989.
41. Weiss S, Bogen B: B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci U S A 86:282, 1989.
42. + T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 148:177, 1993.
43. Bogen B, Gleditsch L, Weiss S, Dembic Z: Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur J Immunol 22:703, 1992.
44. + T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 91:5700, 1994.
45. + T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 25:3079, 1995.
46. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26:2671, 1996.
47. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86:3043, 1995.
48. Kwak LW, Pennington R, Longo DL: Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumorderived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 87:3053, 1996.
49. Yamamoto H, Araki K, Bitoh S, Takata M, Takahashi S, Fujimoto S: Cytotoxic T lymphocyte clone recognizing self idiotype: its regulatory role in antibody production. Eur J Immunol 17:719, 1987.
50. Cao W, Myers-Powell BA, Braciale TJ: Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med 179:195, 1994.
51. Chakrabarti D, Ghosh SK: Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. I. Role of idiotypic immunoglobulin. Cell Immunol 142:54, 1992.
52. Chakrabarti D, Ghosh SK: Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. II. Characterization of anti-idiotypic CTL lines and clones. Cell Immunol 144:443, 1992.
53. Chakrabarti D, Ghosh SK: Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. III. MHC class I-restricted CTL recognizes the processed form(s) of idiotype. Cell Immunol 144:455, 1992.
54. Bergenbrant S, Yi Q, Osterborg A, Björkholm M, Osby E, Mellstedt H, Lefvert AK, Holm G: Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 92:840, 1996.
55. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B cell lymphoma - long-term results of a clinical trial. Blood 89:3129, 1997.
56. Silacci P, Mottet A, Steimle V, Reith W, Mach B: Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med 180:1329, 1994.
57. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345:1016, 1995.
58. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992.
59. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271, 1991.
60. Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10, 1997.
61. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czenzinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996.
62. + CTLs from naive precursors. J Immunol 153:996, 1994.
63. + T cell lines from naive precursors. Eur J Immunol 25:1206, 1995.